BioAge Labs Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
BIOA$5.78+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Unaudited Conde nsed Consolidated Statements of Cash Flows
(in thousands)
| Nine Months Ended | ||
|---|---|---|
| September 30, | ||
| 2024 | 2023 | |
| OPERATING ACTIVITIES | ||
| Net loss | $(49,980) | $(42,896) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 4,258 | 2,249 |
| Depreciation expense | 120 | 121 |
| Loss on extinguishment of debt | 250 | — |
| Non-cash interest expense | 987 | 4,573 |
| Non-cash lease expense | 3 | 2 |
| Loss from changes in fair value on derivative liability and warrants | 384 | 4,910 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,644) | (145) |
| Accounts payable | 132 | (1,705) |
| Accrued expenses and other current liabilities | 2,419 | 719 |
| Deferred grant income | (3,313) | 3,313 |
| Net cash used in operating activities | (46,384) | (28,859) |
| INVESTING ACTIVITIES | ||
| Purchase of property and equipment | (340) | (166) |
| Purchases of investments | — | (100) |
| Net cash used in investing activities | (340) | (266) |
| FINANCING ACTIVITIES | ||
| Proceeds from issuance of convertible notes | — | 23,500 |
| Issuance costs paid on convertible notes | — | (46) |
| Proceeds from term loan | — | 12,500 |
| Issuance costs paid on term loan | — | (4) |
| Proceeds from Series D issuance | 170,000 | — |
| Issuance costs paid on Series D issuance | (542) | — |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 184,140 | — |
| Issuance costs paid on initial public offering and private placement | (3,268) | |
| Proceeds from issuance of common shares through private placement, net of placement agent fees | 9,858 | — |
| Term loan principal payments | (4,500) | — |
| Proceeds from issuance of common shares upon stock option exercises | 609 | — |
| Net cash provided by financing activities | 356,297 | 35,950 |
| Effect of changes in exchange rate on cash, cash equivalents, and restricted cash | (56) | 65 |
| Net increase in cash, cash equivalents and restricted cash | 309,517 | 6,890 |
| Cash, cash equivalents and restricted cash at beginning of period | 24,957 | 27,644 |
| Cash, cash equivalents and restricted cash at end of period | $334,474 | $34,534 |
| Supplemental non-cash disclosure: | ||
| Unpaid equity issuance costs included in accounts payable and accrued expenses | $1,249 | $— |
| Conversion of convertible promissory notes into Series D-1 redeemable convertible preferred stock | $40,651 | $— |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | $342,831 | $— |
| Cash paid for interest | $1,145 | $687 |
| Right-of-use assets obtained in exchange for lease obligation | $282 | $407 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.